The Regis Healthcare Ltd (ASX: REG) share price is in focus as the company holds its annual general meeting (AGM). In FY25, the aged care provider reported FY25 revenue of $1.16 billion, up 14.5%, and underlying EBITDA climbing 17.4% to $125.8 million.
What did Regis Healthcare report in FY25?
- Revenue from services: $1,161.3 million, up 14.5% on the prior year
- Underlying EBITDA: $125.8 million, up 17.4%
- Underlying NPAT: $53.4 million, up 37.3%
- Net cash position: $192.5 million, up 196.6%
- Final dividend: 8.13 cents per share (70% franked); full-year dividend 16.22 cents per share (100% of NPAT)
- Mature homes average occupancy: 95.6%
What else do investors need to know?
Regis Healthcare continued to expand its national footprint, adding over 1,500 net beds in the past two years through acquisitions and new developments. The company finalised the purchase of four Rockpool homes (600 beds) in September 2025 and expects to complete the OC Health acquisition (two homes, 230 beds) in December, lifting its total beds to more than 8,400.
Greenfield growth remains a strategic focus, with construction underway at multiple sites and a pipeline of nine development locations nationally. Regis also improved key care outcomes, employee engagement, and worker safety, creating both operational and financial benefits.
What's next for Regis Healthcare?
Looking ahead, Regis Healthcare is maintaining its guidance for underlying FY26 EBITDA between $130 million and $135 million, expecting structural support from a growing and ageing population along with recent funding reforms. The company is targeting 10,000 beds by FY28, backed by a robust balance sheet and disciplined acquisition strategy.
Management expects sustained high occupancy and ongoing development activity. New government reforms, including the Aged Care Act and revised funding models, are anticipated to support longer-term earnings growth and margin improvements.
Regis Healthcare share price snapshot
Over the past 12 months, Regis Healthcare shares have risen 20%, outperforming the S&P/ASX 200 Index (ASX: XJO) which has risen 4% over the same period.
